Skip to main content

PROFESSIONAL EDUCATIONAL RESOURCES

PROFESSIONAL EDUCATIONAL RESOURCES

Materials to help you make informed treatment decisions are available for downloading, sharing with colleagues, or delivery to your office.

AN OVERVIEW OF ESPEROCT®.

Presented by Dr. Tami Singleton

Chief of Pediatric Hematology and Director of the Hemophilia Treatment Center, Mississippi Center for Advanced Medicine 


In this video, Dr. Tami Singleton presents the clinical characteristics of, and her perspective on, extended half-life Esperoct®.

PROFESSIONAL ORGANIZATIONS

Connect your patients with hemophilia A resources, available on Esperoct.com and ready to share.

Connect your patients with hemophilia A resources, available on Esperoct.com and ready to share.

Questions about Esperoct®? We’re here to help.

Enter your zip code to find a Novo Nordisk Representative.

How to order Esperoct®.

Operators are always available to assist with your product order.

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information